SynthesisFrontiers in aging neuroscience2022
Efficacy and Safety of Probiotics for the Treatment of Alzheimer's Disease, Mild Cognitive Impairment, and Parkinson's Disease: A Systematic Review and Meta-Analysis.
Synthesis in Frontiers in aging neuroscience, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 51 papers, 7 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
51 citing papers in PubMed, 7 syntheses or guidelines pooled it, 83 citations in OpenAlex.
- Role of Probiotics in Management of Depressive Symptoms and Cognitive Impairment in Patients With Depression: An Updated Analysis of Trials.Brain and behavior · 2025Pooled it
- Mitotherapy in Alzheimer's and Parkinson's diseases: A systematic review of preclinical studies.BMC neurology · 2025Pooled it
- Effect of probiotics on cognitive function and cardiovascular risk factors in mild cognitive impairment and Alzheimer's disease: an umbrella meta-analysis.Journal of health, population, and nutrition · 2025Pooled it
- Efficacy and safety of probiotics combined with bismuth-containing quadruple therapy forFrontiers in microbiology · 2025Pooled it
- Effects of microbiome-based interventions on neurodegenerative diseases: a systematic review and meta-analysis.Scientific reports · 2024Pooled it
- Probiotics for constipation in Parkinson's: A systematic review and meta-analysis of randomized controlled trials.Frontiers in cellular and infection microbiology · 2022Pooled it
- Efficacy and safety of probiotics in Parkinson's constipation: A systematic review and meta-analysis.Frontiers in pharmacology · 2022Pooled it
- Effects of intensive lifestyle changes on the progression of mild cognitive impairment or early dementia due to Alzheimer's disease: a randomized, controlled clinical trial.Alzheimer's research & therapy · 2024Trial
- Effect of Probiotic Bifidobacterium breve in Improving Cognitive Function and Preventing Brain Atrophy in Older Patients with Suspected Mild Cognitive Impairment: Results of a 24-Week Randomized, Double-Blind, Placebo-Controlled Trial.Journal of Alzheimer's disease : JAD · 2022Trial
- Taurochenodeoxycholic acid alleviates MPPIBRO neuroscience reports · 2026Article
- Functional Foods and Micro- and Nanoplastics: Advances in Precision Nutritional Medicine for Oral-Gut-Brain Axis Health.Antioxidants (Basel, Switzerland) · 2026Review
- Plant-derived Natural Products in Neurological and Psychiatric Disorders: Mechanisms of Action and Synergistic Roles with Probiotics.Molecular neurobiology · 2026Review
- Probiotic and Dietary Supplements Intervention in Age-Related Neurodegenerative Disorders.Microorganisms · 2026Review
- An attention-augmented multimodal classification of alzheimer's disease and parkinson's disease vs healthy controls using MRI, EEG, and SNP data.Scientific reports · 2026Article
- Attenuating Neurotoxicity Through Fecal Microbiota Transplant: Mechanisms and Therapeutic Potential.Molecular neurobiology · 2025Review
- Aryl Hydrocarbon Receptor in Health and Disease.MedComm · 2025Review
- Gut-Brain Axis and Perioperative Gut Microbiome in Postoperative Cognitive Dysfunction: Implications for Neurosurgical Patients.Medical sciences (Basel, Switzerland) · 2025Review
- Probiotic effects on cognitive performance, hippocampal oxidative stress, and structural damage induced by icv STZ in Alzheimer-like rat model.Brain structure & function · 2025Article
- Probiotic Supplementation Improves the Clinical Measures of Cognition in Patients With Mild Cognitive Impairment.Cureus · 2025Review
- The effect of probiotic supplementation on constipation in patients with Parkinson's disease: A randomized controlled trial.Current journal of neurology · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundAlzheimer's disease (AD) and Parkinson's disease (PD) are two of the most common neurodegenerative diseases, and mild cognitive impairment (MCI) is considered a prodromal stage of clinical AD. Animal studies have shown that probiotics can improve cognitive function and mitigate inflammatory response, however, results from randomized controlled trials in humans are still unclear.
objectivesA systematic review and meta-analysis was conducted to evaluate the efficacy and safety of probiotic therapy on cognitive function, oxidative stress, and gastrointestinal function in patients with AD, MCI, and PD.
methodsWe searched the electronic databases such as PubMed, EMBASE, Cochrane Library until October 2020 for the eligible randomized controlled trials, as well as the unpublished and ongoing trials. Our primary endpoints were cognitive function, inflammatory and oxidative stress biomarkers, gastrointestinal function, and adverse events.
resultsAfter screening 2,459 titles and abstracts about AD or MCI, we selected 6 eligible studies (
conclusionOur analyses suggest that probiotics can improve cognitive and gastrointestinal symptoms in patients with AD, MCI, and PD, which is possibly through reducing inflammatory response and improving lipid metabolism. The safety has also been proven. However, more RCTs with rigorous study design are needed to support our findings. SYSTEMATIC REVIEW REGISTRATION: PROSPERO, Identifier: CRD42021231502.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.